Dr. Jingsong Wang

Dr. Jingsong Wang is the Principal Founder, Chairman and Chief Executive Officer of Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. Wang holds both an M.D. in clinical medicine from Xuzhou Medical College (1986) and a Ph.D. in molecular pharmacology from China Pharmaceutical University (2011), complemented by a master's degree in medical science (immunology) from Jilin University (1989).

Wang served as a research and clinical fellow in rheumatology at Brigham and Women's Hospital and Harvard Medical School from June 2001 to June 2005, and obtained physician qualification from the Commonwealth of Massachusetts Board of Registration in Medicine in May 2002. He is a former attending physician and clinical fellow at Harvard Medical School and serves as an Adjunct Assistant Professor of Medicine at the University of Pennsylvania.

Career history

• Associate Director of Translational Medicine at Wyeth (July 2005 – May 2007)
• Director of Clinical Discovery Immunology at Bristol-Myers Squibb (June 2007 – November 2011)
• Head of China Research and Development at Sanofi (November 2011 – December 2015)
• Head of Translational Medicine, Asia Pacific, at Sanofi (prior to founding Harbour BioMed)
• Founder, Chairman and CEO of Harbour BioMed (2016 – present)

What Dr. Wang could bring to his role at Harbour BioMed: His extensive background spanning clinical rheumatology, immunology research at Harvard, and strategic leadership across major pharmaceutical companies (Wyeth, Bristol-Myers Squibb, Sanofi) uniquely positions him to guide Harbour BioMed's therapeutic development strategy and platform commercialization. His company achieved profitability for a second consecutive year in 2024 following more than eight years of sustained development, demonstrating his ability to build sustainable, innovation-driven business models in competitive biotech markets.